Analytical Tools for RNA Therapeutics

Rockland has a demonstrated history of successful generation of antibodies against different types of nucleic acid targets including modified backbones and nucleosides. We have developed panels of validated specialty reagents directed against common modifications used in RNA therapeutics, such as phosphorothioate (PS), 2’-methoxyethyl (2’-MOE), 2’-O-methyl (2’-OMe), and others, that are readily available, saving significant time compared to traditional programs that may take more than 12 months. The methods we use to produce oligonucleotide conjugates are available as a contract service specific to your needs.

Custom Antibodies to Nucleic Acids

We are experienced in working with a variety of chemistries, including:

Conventional Oligonucleotides
DNA-RNA Hybrids
Modified Oligonucleotides
Single Stranded Oligonucleotide Mixtures (Cocktails)
Single Stranded RNA (ssRNA)
Double Stranded RNA (dsRNA)


Targeted RNA Therapeutic Modalities

Modified Oligonucleotides modified OligoAntisense Oligonucleotides (ASO)
RNA Interference (RNAi)
Small interfering RNA (siRNA)
Micro RNA (miRNA)
Messenger RNA (mRNA) mRNA Vaccine Development & Replacement Therapy
Other Modalities
Short hairpin (shRNA)

The Immunoassay Advantage

Choosing oligonucleotide drug candidates during early discovery stages and further assessment of these candidates in the pre-clinical stages of drug development can be time-consuming and laborious. Moreover, assessing pharmacokinetics (PK) by further elucidating absorption, distribution, metabolic, and excretion (ADME) profiles of a given oligonucleotide or multiple oligonucleotides, in addition to understanding pharmacodynamic (PD) properties, is essential to the movement of the best candidates in the pipeline. Although current assays can address these parameters, they have certain disadvantages, such as the need for multiple probes, sequence specificity, decreased sensitivity for larger oligonucleotides, or handling and disposal of radioactive materials.

Immunoassays provide a novel approach for collecting critical data to further shed light on PK/ADME parameters and combat some disadvantages of the current methods; however, antibody development to oligonucleotides can be challenging and is typically specific to a particular sequence. Rockland has a demonstrated history of successful custom antibody generation against different nucleic acid targets, including modified oligonucleotides and nucleosides, heteroduplexes, and single-stranded and double-stranded DNA and RNAs.

All of Rockland’s ModDetect™ and custom anti-oligonucleotide antibodies are designed, developed, optimized, and validated in our facilities outside Philadelphia, Pennsylvania, USA, where we ensure supply chain security and protect client confidentiality and intellectual property.